Translating claims-based CHA
Aged
Aged, 80 and over
Anticoagulants
/ administration & dosage
Atrial Fibrillation
/ drug therapy
Cohort Studies
Female
Follow-Up Studies
Hemorrhage
/ chemically induced
Hospitalization
/ trends
Humans
Insurance Claim Review
/ standards
International Classification of Diseases
/ standards
Male
Medicare
/ standards
Risk Factors
United States
/ epidemiology
ICD-10-CM
diagnosis codes
mapping
oral anticoagulants
pharmacoepidemiology
risk scores
Journal
Pharmacoepidemiology and drug safety
ISSN: 1099-1557
Titre abrégé: Pharmacoepidemiol Drug Saf
Pays: England
ID NLM: 9208369
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
04
12
2019
revised:
27
01
2020
accepted:
02
02
2020
pubmed:
19
2
2020
medline:
25
3
2021
entrez:
19
2
2020
Statut:
ppublish
Résumé
The CHA We compared the distributions of CHA Forward-backward mapping produced higher CHA Existing mapping strategies generally preserved the distributions of CHA
Substances chimiques
Anticoagulants
0
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
409-418Subventions
Organisme : FDA HHS
ID : HHSF223200910006I
Pays : United States
Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
DeFilippis AP, Young R, Carrubba CJ, et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med. 2015;162(4):266-275.
Sayin M, Cetiner M, Karabag T, et al. Framingham risk score and severity of coronary artery disease. Herz. 2014;39(5):638-643.
Roe MT, Chen AY, Thomas L, et al. Predicting long-term mortality in older patients after non-ST-segment elevation myocardial infarction: the CRUSADE long-term mortality model and risk score. Am Heart J. 2011;162(5):875-883.e871.
Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102(17):2031-2037.
Dite GS, MacInnis RJ, Bickerstaffe A, et al. Breast cancer risk prediction using clinical models and 77 independent risk-associated SNPs for women aged under 50 years: Australian breast cancer family registry. Cancer Epidemiol. 2016;25(2):359-365.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of atrial fibrillation. JAMA. 2001;285(22):2864-2870.
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-272.
Pisters R, Lane DA, Nieuwlaat R, De Vos CB, Crijns HJ. Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart survey. Chest. 2010;138(5):1093-1100.
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.
Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010;159(3):331-339.
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891.
Loo SY, Coulombe J, Dell'Aniello S, Brophy JM, Suissa S, Renoux C. Comparative effectiveness of novel oral anticoagulants in UKpatients with non-valvular atrial fibrillation and chronic kidney disease: a matched cohort study. BMJ Open. 2018;8(1):e019638.
Go AS, Singer DE, Toh S, et al. Outcomes of Dabigatran and warfarin for atrial fibrillation in contemporary practice: a retrospective cohort study. Ann Intern Med. 2017;167(12):845-854.
Graham DJ, Reichman ME, Wernecke M, et al. Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med. 2016;176(11):1662-1671.
Lauffenburger JC, Farley JF, Gehi AK, Rhoney DH, Brookhart MA, Fang G. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc. 2015;4(4):e001798.
Seeger JD, Bykov K, Bartels DB, Huybrechts K, Zint K, Schneeweiss S. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost. 2015;114(6):1277-1289.
Navar-Boggan AM, Rymer JA, Piccini JP, et al. Accuracy and validation of an automated electronic algorithm to identify patients with atrial fibrillation at risk for stroke. Am Heart J. 2015;169(1):39-44. e32.
Ding M, Fratiglioni L, Johnell K, Fastbom J, Ljungdahl M, Qiu C. Atrial fibrillation and use of antithrombotic medications in older people: a population-based study. Int J Cardiol. 2017;249:173-178.
Panozzo CA, Woodworth TS, Welch EC, et al. Early impact of the ICD-10-CM transition on selected health outcomes in 13 electronic health care databases in the United States. Pharmacoepidemiol Drug Saf. 2018;27(8):839-847.
Simard M, Sirois C, Candas B. Validation of the combined comorbidity index of Charlson and Elixhauser to predict 30-day mortality across ICD-9 and ICD-10. Med Care. 2018;56(5):441-447.
Fung KW, Richesson R, Smerek M, et al. Preparing for the ICD-10-CM transition: automated methods for translating ICD codes in clinical phenotype definitions. eGEMs. 2016;4(1).
Curtis LH, Weiner MG, Boudreau DM, et al. Design considerations, architecture, and use of the mini-sentinel distributed data system. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):23-31.
FDA. FDA's sentinel initiative. 2018; https://www.fda.gov/safety/fdassentinelinitiative/ucm2007250.htm. Accessed August, 2018.
Sentinel. Routine Querying System. 2018; https://www.sentinelinitiative.org/sentinel/surveillance-tools/routine-querying-tools/routine-querying-system.
Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for non-valvular atrial fibrillation. Circulation. 2015;131(2):157-164.
Vinereanu D, Lopes RD, Bahit MC, et al. A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial. Lancet. 2017;390(10104):1737-1746.
Student. The probable error of a mean. Biometrika. 1908;6:1-25.
The Joint Commission. Specifications Manual for Joint Commission National Quality Measures (v2012A). 2016; https://manual.jointcommission.org/releases/archive/TJC2012A/.
Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39(4):561-577.
Hosmer DW, Lemesbow S. Goodness of fit tests for the multiple logistic regression model. Commun Stat Theory Method. 1980;9(10):1043-1069.
Senoo K, Proietti M, Lane DA, Lip GY. Evaluation of the HAS-BLED, ATRIA, and ORBIT bleeding risk scores in patients with atrial fibrillation taking warfarin. Am J Med. 2016;129(6):600-607.
Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY. Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or Acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol. 2012;60(9):861-867.
Chao T-F, Liu C-J, Wang K-L, et al. Using the CHA2DS2-VASc score for refining stroke risk stratification in ‘low-risk’ Asian patients with atrial fibrillation. J Am Coll Cardiol. 2014;64(16):1658-1665.
Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124.